Systemically important companies in the Swiss healthcare market
We have had an extraordinary and challenging six months. The coronavirus
(COVID-19) and the associated measures implemented by the authorities to
combat this pandemic meant that the entire Galenica Group was stretched to
its limits in its core business from early March. Under these most difficult and
unique circumstances, our employees made every effort to ensure the supply
of medicines and healthcare products to the Swiss population. In doing so, the
protection of patients and employees was always the top priority. The pandemic
clearly showed the key role that the Galenica Group, with its systemically
important companies, plays in the Swiss healthcare market.
In light of the extraordinary situation that we had to manage, we achieved a solid result in the first half of 2020, with sales of CHF 1,690.4 million and an EBIT of CHF 82.3 million.
Bern, 4 August 2020